NutriBand (NTRB) Current Deferred Revenue (2018 - 2026)
NutriBand (NTRB) posted Current Deferred Revenue of $30406.0 for Q2 2026, down 74.73% sequentially from $120303.0 in Q1 2026, and down 31.95% YoY from $44680.0 in Q2 2025.
NutriBand (NTRB) Current Deferred Revenue (2018 - 2026) Analysis & Trends
NutriBand has reported Current Deferred Revenue for 8 years, with the latest figure at $30406.0 in Q2 2026.
- Quarterly Current Deferred Revenue fell 31.95% year-over-year to $30406.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $30406.0 (down 31.95% YoY) and the FY2026 annual result came in at $120303.0, down 22.82% from the prior year.
- Current Deferred Revenue declined to $30406.0 in Q2 2026 per NTRB's latest filing, from $120303.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $269345.0 in Q2 2024 and troughed at $6974.0 in Q4 2025.
- A 5-year average of $140338.6 and a median of $156691.0 in 2024 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2022 and 2025: Current Deferred Revenue soared 125.51% in 2022, then tumbled 96.81% in 2025.
- Over 5 years, Current Deferred Revenue stood at $201990.0 in 2022, then decreased by 16.09% to $169495.0 in 2023, then advanced by 29.13% to $218868.0 in 2024, then sank by 96.81% to $6974.0 in 2025, then jumped by 335.99% to $30406.0 in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $30406.0, $120303.0, and $6974.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | NutriBand | 57.74 Mn | 53.73 Mn | 196,801.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 30,406.00 |
| Jan 31, 2026 | 120,303.00 |
| Oct 31, 2025 | 6,974.00 |
| Jul 31, 2025 | 19,419.00 |
| Apr 30, 2025 | 44,680.00 |
| Jan 31, 2025 | 155,880.00 |
| Oct 31, 2024 | 218,868.00 |
| Jul 31, 2024 | 179,576.00 |
| Apr 30, 2024 | 269,345.00 |
| Jan 31, 2024 | 157,502.00 |
| Oct 31, 2023 | 169,495.00 |
| Jul 31, 2023 | 217,890.00 |
| Apr 30, 2023 | 188,697.00 |
| Jan 31, 2023 | 162,903.00 |
| Oct 31, 2022 | 201,990.00 |
| Jul 31, 2022 | 145,914.00 |
| Apr 30, 2022 | 129,986.00 |
| Jan 31, 2022 | 106,267.00 |
| Oct 31, 2021 | 239,582.00 |
| Jul 31, 2021 | 64,704.00 |